MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Precipio Gross Profit 2011-2025 | PRPO
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.02 M | 2.51 M | 2.39 M | 1.15 M | 219 K | 225 K | 292 K | -205 K | -287 K | 9.72 M | 12.5 M | 15 M | 18.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.4 M | -287 K | 5.23 M |
Quarterly Gross Profit Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 M | 2.43 M | 2.14 M | - | 2.28 M | 1.72 M | 920 K | - | 1.88 M | 1.37 M | 749 K | - | 436 K | 773 K | 703 K | - | 528 K | 751 K | 468 K | - | 377 K | 171 K | 125 K | - | 28 K | 172 K | 38 K | - | -11 K | 175 K | 24 K | - | -77 K | -24 K | 66 K | - | 134 K | 263 K | -269 K | - | -115 K | -23 K | 285 K | 2.62 M | 1.72 M | 2.39 M | 2.49 M | 2.08 M | 2.45 M | 2.97 M | 3.26 M | 3.54 M | 3.8 M | 4.56 M | 3.1 M | 5.28 M | 4.44 M | 4.56 M | 4.15 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.28 M | -269 K | 1.53 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
53 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Danaher Corporation
DHR
|
14.2 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
DexCom
DXCM
|
2.29 B | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
493 M | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
144 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
290 M | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
Organovo Holdings
ONVO
|
1.87 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
366 K | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
219 M | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Mettler-Toledo International
MTD
|
2.33 B | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
2.86 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.1 | - | $ 2.74 M | USA |
 |
Pacific Biosciences of California
PACB
|
52.8 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
PerkinElmer
PKI
|
523 M | - | -0.91 % | $ 14.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Myriad Genetics
MYGN
|
585 M | $ 6.55 | -0.15 % | $ 593 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 254.46 | 0.52 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 183.68 | 0.33 % | $ 15.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
2.38 B | $ 688.18 | 0.86 % | $ 56.8 B | USA |